Such activation depends on type 1 conventional dendritic cells (cDC1), which excel in cross-presentation of tumor-associated antigens (1–3), secrete immunostimulatory factors (2, 4–7), and sustain long-term CD8+T cell antitumor immunity (8). This evidence concerns the gene CD8A and neoplasm.